Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04401579 · OUTCOME

Duration of New Non-invasive Ventilation or High Flow Oxygen Use

Adaptive COVID-19 Treatment Trial 2 (ACTT-2) · Source last updated 2022-03-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Days
Interval / dispersion
Inter-Quartile Range
Time frame
Day 1 through Day 29

What was measured

Duration of new non-invasive ventilation or high flow oxygen use was measured in days among participants who were not on non-invasive ventilation or high-flow oxygen use at baseline, determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die

Analysis population: The analysis population is restricted to randomized participants who were not on non-invasive ventilation or high-flow oxygen at baseline but who subsequently required non-invasive or high-flow oxygen.

Groups in this outcome

Remdesivir Plus Baricitinib

200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.

Remdesivir Plus Placebo

200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Remdesivir Plus Baricitinib70
Remdesivir Plus Placebo82

Reported measurements

Including imputations for participants who died

Analysis denominator · Participants

GroupSource count
Remdesivir Plus Baricitinib70
Remdesivir Plus Placebo82
Values in Days · Interval/dispersion: Inter-Quartile Range
GroupValueSpreadLowerUpperComment
Remdesivir Plus Baricitinib6Not reported315Not reported
Remdesivir Plus Placebo4.5Not reported211Not reported
Among participants who did not die

Analysis denominator · Participants

GroupSource count
Remdesivir Plus Baricitinib65
Remdesivir Plus Placebo72
Values in Days · Interval/dispersion: Inter-Quartile Range
GroupValueSpreadLowerUpperComment
Remdesivir Plus Baricitinib5Not reported310Not reported
Remdesivir Plus Placebo4Not reported27Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        3
        upper Limit
        15
        value
        6
      2. group Id
        OG001
        lower Limit
        2
        upper Limit
        11
        value
        4.5
    denoms
    1. counts
      1. group Id
        OG000
        value
        70
      2. group Id
        OG001
        value
        82
      units
      Participants
    title
    Including imputations for participants who died
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        3
        upper Limit
        10
        value
        5
      2. group Id
        OG001
        lower Limit
        2
        upper Limit
        7
        value
        4
    denoms
    1. counts
      1. group Id
        OG000
        value
        65
      2. group Id
        OG001
        value
        72
      units
      Participants
    title
    Among participants who did not die
denoms
  1. counts
    1. group Id
      OG000
      value
      70
    2. group Id
      OG001
      value
      82
    units
    Participants
description
Duration of new non-invasive ventilation or high flow oxygen use was measured in days among participants who were not on non-invasive ventilation or high-flow oxygen use at baseline, determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die
dispersion Type
Inter-Quartile Range
groups
  1. description
    200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.
    id
    OG000
    title
    Remdesivir Plus Baricitinib
  2. description
    200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.
    id
    OG001
    title
    Remdesivir Plus Placebo
param Type
MEDIAN
population Description
The analysis population is restricted to randomized participants who were not on non-invasive ventilation or high-flow oxygen at baseline but who subsequently required non-invasive or high-flow oxygen.
reporting Status
POSTED
time Frame
Day 1 through Day 29
title
Duration of New Non-invasive Ventilation or High Flow Oxygen Use
type
SECONDARY
unit Of Measure
Days

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice